Several in vitro [44-47] and in vivo studies [45-48], based upon the use of Hsp90-binding agents, such as geldanamycin derivatives, have indicated this protein as an alternative molecular target for human breast cancer therapy. This evidence concerns the gene HSP90AB1 and breast carcinoma.